Glycomic therapeutics refers to the development of glycomics-based approaches in the field of therapeutics. Glycome is the complete set of glycans in a cell or organism, which is important for unraveling the complexity of biological systems and their implications for health and disease. Glycan plays important roles in various biological processes, including cell signaling, immune response, and disease development.
The main glycomic therapeutics class types are isolated, and synthetic. Isolated glycomic therapy refers to the study or analysis of glycans in isolation, focusing specifically on the structural and functional characterization of individual glycan molecules and the therapeutic approach that involves the use of synthetic glycans or glycan-based molecules for the diagnosis and treatment of diseases or medical conditions. The various structures are glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins and heparin based glycans, targeting glycosphingolipids, others with various mode of actions such as inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin and enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1, 2 and 3, beta and gamma interferons, others. The various indications are thrombosis and chemoprophylaxis, anemia, anti-adhesive and anti-inflammatory, cataracts; Gaucher’s disease, mps-1 and IV, cancer, Alzheimer's disease, influenza type A and B, and others.
The global glycomic therapeutics market is segmented -
1) By Class: Isolated, Synthetic
2) By Structures: Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins And Heparin Based Glycans, Targeting Glycosphingolipids, Other Structures
3) By Mode Of Action: Inhibits Neuraminidase, Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate, Erythropoietin And Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthase, Interleukin 1, 2 And 3, Beta And Gamma Interferons, Other Mode Of Action
4) By Indications: Thrombosis And Chemoprophylaxis, Anemia, Anti-Adhesive And Anti-Inflammatory, Cataracts, Gaucher’s Disease, Mps-1 And IV, Cancer, Alzheimer’s Disease, Influenza Type A And B, Other Indications
The global glycomic therapeutics market size is expected to grow from $121.85 billion in 2022 to $141.31 billion in 2023 at a compound annual growth rate (CAGR) of 16.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of glycomic therapeutics market is expected to reach $255.71 billion in 2027 at a CAGR of 16.0%.
The increase in the prevalence of diabetes is expected to drive the growth of the glycomic therapeutics market. Diabetes is a chronic medical condition that affects the body's ability to regulate blood sugar (glucose) levels. In diabetes, alterations in glycans have been observed, which can contribute to insulin resistance and other metabolic abnormalities. Specific glycan patterns serve as biomarkers for diagnosing diabetes, predicting its progression, and monitoring treatment responses. For instance, in May 2023, according to the report published by the National Center for Health Statistics, a U.S.-based government agency that provides statistical information to guide actions and policies to improve the public health of the American people, the percentage of diagnosed diabetes for adults aged 18 and over, United States increased from 9.3% in 2020 to 9.6% in 2021. Therefore, the increase in the prevalence of diabetes is driving the growth of the glycomic therapeutics market.
Major players in the glycomic therapeutics market are F Hoffmann-La Roche Ltd., Bayer AG, Sanofi SA, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Merck KGaA, ICON plc, Agilent Technologies Inc., AMS Bio, Shimadzu Corporation, Waters Corporation, Bruker Corporation, BioMarin Pharmaceutical Inc., Bio Techne Corp., Promega Corporation, Halozyme Therapeutics Inc., Takara Bio Inc., Vector Laboratories, New England Biolabs Inc., Protalix Biotherapeutics Inc., Genovis AB, Ray Biotech Life Inc., IEC Group, Ludger Ltd, Z Biotech LLC, Alzheon Inc., and GlycoMar Limited
Product innovation is a key trend gaining popularity in the glycomic therapeutics market. Major companies operating in the glycomic therapeutics sector are focused on developing new technological and innovative solutions to strengthen their position in the market. For instance, in April 2022, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company is discovering advanced therapies, launched a novel fixed-dose combination (FDC) of a DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, with Pioglitazone to improve glycemic control and to reduce insulin resistance in type 2 diabetes patients.
In May 2022, Halozyme Therapeutics, a US-based biotechnology company, acquired Antares Pharma Inc. for $960 million. This purchase enhanced the pipeline portfolio of novel treatments employing its superior drug delivery methods, which have increased safety and efficacy, convenience, tolerability, and patient comfort and adherence. Antares Pharma Inc is a US-based pharmaceutical firm.
North America was the largest region in the glycomic therapeutics in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomic therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the glycomic therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The glycomic therapeutics market consists of sales of investigational glycomic therapeutics and therapeutic glycomic that target glycans or glycan-related pathways for the diagnosis and treatment of diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The glycomic therapeutics market research report is one of a series of new reports from The Business Research Company that provides glycomic therapeutics market statistics, including glycomic therapeutics industry global market size, regional shares, competitors with a glycomic therapeutics market share, detailed glycomic therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the glycomic therapeutics industry. This glycomic therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.